The Transforming CURES Initiative (TCI) – Intercepting Progression to Advanced Myeloid Blood Cancers is the result of a partnership between the LLS and Janssen Pharmaceuticals, Inc., a pharmaceutical company of Johnson & Johnson. The purpose of the grant is to support research able to identify and develop novel, safe and effective treatment paradigms for patients with hematological malignancies, and it consists of $400,000 over a period of three years.

Find out more here.